Latest Breaking News On - Oncternal therapeutics inc - Page 1 : vimarsana.com

Oncternal Therapeutics : Corporate Presentation, June 2024

TA R G E T I N G C A N C E R N e w S c i e n c e . N e w C a n c e r T h e r a p i e s . N e w H o p e . .

Exchange commissionDrug administrationUs securities exchangeOncternal therapeutics incExchange actOncternal therapeuticsPresentation june

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Salim yazjiSafety review committeeOncternal therapeutics incChief medical officer

StockNews com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […]

Oncternal therapeutics company profileSecurities exchange commissionOncternal therapeutics incPasadena private wealthOncternal therapeuticsGet free reportDirector robert james willsExchange commissionPrivate wealthFree reportOrphan receptorOncternal therapeutics daily

Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Sunday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $28.00 to $19.00 and set a buy rating on the stock in a research note […]

Pasadena private wealthQuantum private wealthOncternal therapeutics incSecurities exchange commissionRichmond brothers incOncternal therapeuticsFree reportGet free reportDirector robert james willsExchange commissionPrivate wealthOrphan receptorOncternal therapeutics daily

Oncternal Therapeutics, Inc (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript

Oncternal Therapeutics, Inc (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Carl byrnesSalim yazjiRichard vincentKemp dolliverRobert burnsJim breitmeyerJames breitmeyerHartaj singhOncternal therapeutics incOppenheimer companyInternational studentsOncternal therapeuticsCall transcript mayFirst quarterChief financialSafe harbor